Dynamic Changes in SDF-1α Levels in Acute and Stabilized Heart Disease
NCT ID: NCT02702752
Last Updated: 2020-07-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-11-30
Study Completion Date
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aims of the present study are to measure dynamic changes over time in the plasma level of SDF-1α in patients with confirmed diagnoses of AMI, AF and CHF and in so doing:
1. Monitor the plasma level of SDF-1α at the diagnosis, during and after the long term treatment of AMI, AF and CHF. The SDF-1α level of patients is expected to decrease during treatment of the aforementioned conditions.
2. Correlate the plasma level of SDF-1α in relation to clinical, biochemical characteristics of Acute Myocardial Infarction(AMI), Atrial Fibrillation(AF) and Congestive Heart Failure (CHF). In so doing, the investigators expect that SDF-1α will correlate with the severity of heart disease.
3. Study the dynamic of SDF-1α pertaining to its property as prognostic indicator for the long term follow up risk of readmission and mortality of patients diagnosed with AMI, AF or CHF.
1. Monitor the plasma level of SDF-1α at the diagnosis, during and after the long term treatment of AMI, AF and CHF. The SDF-1α level of patients is expected to decrease during treatment of the aforementioned conditions.
2. Correlate the plasma level of SDF-1α in relation to clinical, biochemical characteristics of Acute Myocardial Infarction(AMI), Atrial Fibrillation(AF) and Congestive Heart Failure (CHF). In so doing, the investigators expect that SDF-1α will correlate with the severity of heart disease.
3. Study the dynamic of SDF-1α pertaining to its property as prognostic indicator for the long term follow up risk of readmission and mortality of patients diagnosed with AMI, AF or CHF.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D in Patients With Heart Failure
NCT00501553
Heart Failure
COMPLETED
Prognostic Value Of Short-Term Follow-up Biomarkers After Discharge In hOspitalized Patients With Acute Heart Failure
NCT04437628
Heart Failure
RECRUITING
Evaluation of Respiratory Parameters and Functional Capacity in Coronary Artery Patients
NCT05549739
Coronary Artery Disease
UNKNOWN
Inflammation, Epigenetics in CHF Patients With AF
NCT07152301
Congestive Heart Failure Chronic
Atrial Fibrillation (Permanent)
COMPLETED
LYmphangiogenesis FacTors in Heart Failure States
NCT03141567
Heart Failure
Heart Failure With Reduced Ejection Fraction
Heart Failure With Normal Ejection Fraction
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
BLOOD SAMPLING AND MEASUREMENT OF SDF-1Α A blood sample of about 5 ml will be sampled by peripheral venepuncture and anticoagulated with heparin. Blood samples will be spun for 15 minutes at 1000g within 30 minutes of collection. The resulting plasma will be stored at -80°C until analysis. Levels of SDF-1α in the plasma will be determined using a commercially available ELISA kit according to the manufacturer's instructions.
Analyses will be performed at the Clinical Research Centre, Copenhagen University Hospital Hvidovre.
PATIENTS Patients are included from the in-patient department of the Department of Cardiology, Hvidovre University Hospital. Patients are eligible for inclusion if diagnosed with myocardial infarction, atrial fibrillation or heart failure, provided they do not suffer from malignant disease, diabetes mellitus types I or II and have a life expectancy of at least one year.
Exclusion criteria are based upon the fact that serum SDF-1α levels are elevated in malignant diseases as SDF-1α contributes to neoangiogenesis of the tumour mass, and SDF-1α levels have recently been demonstrated to be elevated in diabetes.
The investigators will include 20 patients with each of the cardiac conditions mentioned as well as a control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
PATIENTS WITH MYOCARDIAL INFARCTION Patients presenting with non-ST elevation myocardial infarction (NSTEMI) are included. The diagnostic criteria are symptoms of cardiac ischaemia (angina or angina-equivalent symptoms) and elevated troponin T (above 14 ng/mL) and/ or ECG changes of ischemia (horizontal or downsloping ST depression ≥ 0.5 mm at the J-point in ≥ 2 contiguous leads).
Patients are excluded if they are diagnosed with a "type 2 myocardial infarction", i.e. myocardial ischaemia due to mismatch between myocardial oxygen demand and supply due to conditions such as severe anaemia, arrhythmia or hypotension. Patients are also excluded if they are not referred for coronary angiography, if they have atrial fibrillation or if they have cardiac failure with LVEF ≤ 40%.
The SDF-1α levels of patients will be measured on the first day of hospitalization, after coronary angiography, before discharge (approximately day 3-5), and three months after inclusion.
PATIENTS WITH ATRIAL FIBRILLATION Patients presenting with ECG-documented atrial fibrillation are included if unstable, i.e. if heart rate exceeds 100 and in-patient treatment is indicated. Patients are excluded if they suffer from unstable ischaemic heart disease (unstable angina or myocardial infarction), heart failure with LVEF ≤ 40% or if the arrhythmia is secondary to another condition such as an infection.
SDF-1α levels will be measured on the first day of the hospitalization, at the time of discharge (after medical or electrical cardioversion or after stabilization of the heart rate) and three months after inclusion.
PATIENTS WITH CONGESTIVE HEART FAILURE Patients are included if presenting with decompensated heart failure. They must have symptoms of heart failure (dyspnoea and/ or oedema) severe enough to warrant in-patient treatment. The diagnosis must be confirmed by echocardiography showing LVEF ≤ 40%. Patients are excluded if suffering from unstable ischaemic heart disease (unstable angina or myocardial infarction) or atrial fibrillation.
The SDF-1α levels of will be measured on the first day of the hospitalization, after medical stabilization at the time of discharge, and three months after inclusion.
PATIENT INCLUSION AND DATA COLLECTION Patient inclusion will take place during three consecutive months. Patients are included within the first day of hospital admittance. Each day, members of the project group will screen all patients admitted within the last day and personally contact those eligible for inclusion. Patients will be informed verbally and given the written participant information. Patients will be given time for consideration and if they accept participation, they will be asked to sign the consent form. Due to the project design, according to which the first blood samples are to be taken within the first day of hospitalization, patients are asked to consent to project participation on the day of initial contact with the research group member. Conversations will be held in a private setting in the department, and patients are invited to bring relations, if they so prefer.
As regards the control group, these will be included from patients initially referred for outpatient evaluation at the Department of Cardiology, but in whom no cardiac disease is found. Members of the project group will screen the patients in the Outpatients Department and personally contact those eligible for inclusion in the control group. The control group will be selected so as to be age-matched with the patients. Information about the project will be provided as for the patients.
Based upon information in the patients' medical files, it will be registered whether patients suffer from hypertension, peripheral vascular disease, stroke, transient cerebral ischaemia, chronic obstructive pulmonary disease or renal insufficiency.
Medication at time of admittance to hospital and medication given during the hospitalization will be registered. Clinical status (dyspnoea, palpitations, oedema, blood pressure and heart rate) at the time of inclusion and at the time discharge from hospital will be noted. This information will be sought from patient files and the Kiso system used for recording vital parameters in patients.
The recorded information (pre-existing conditions, medication and clinical status at the two time-points) will be available for the project group. This information will be used for background demographics, in the evaluation of how levels of SDF-1α correlate to clinical status, and to allow for correction of factors, such as medication, on the levels of SDF-1α.
FOLLOW-UP All patients are expected to be seen in the Outpatients' Department 2-3 months after discharge from hospital. This appointment is part of the standard treatment and control plan for patients with AF, CHF and NSTEMI, respectively and not arranged as a part of the project. Certain information will be registered from the patient files at the time of follow-up: Clinical status (NYHA class, oedema, pulmonary congestion, and angina), heart rhythm, medication, and any intercurrent hospital admissions.
One year after inclusion, patient files will be reviewed and the following information registered: Whether the patient is alive and any cardiovascular rehospitalisation. In the case of hospitalization, the date of admission, duration and diagnosis will be registered. Statistical considerations and data analysis Baseline data of SDF-1α levels and patient demographics (including comorbidities and use of medication) will be evaluated using descriptive statistics. Normally distributed data will be presented as mean and standard deviation, whereas skewed data will be presented as median and range. If necessary, skewed data will be transformed.
The influence of patient characteristics (such as age, sex and comorbidities) on SDF-1α levels will be evaluated using multiple regression analysis with SDF-1α level as dependent variable and patient characteristics as explanatory variables. SDF-1α levels will be compared between the patient groups using analysis of variance (ANOVA).
Within each group of patients, the changes in SDF-1α levels over time (three time points) will be analysed using ANOVA.
The investigators have previously measured SDF-1α levels in patients with various types of AF (permanent versus paroxysmal). Based upon these results (SDF-1α levels and standard deviations in the different groups), the investigators have estimated that the proposed sample size of 20 patients in each disease group will confer the study sufficient statistical power.
The statistical analyses will be performed in collaboration with statistician Steen Ladelund (Clinical Research Centre, Hvidovre University Hospital).
THE RESEARCH GROUP
The study will be conducted in close collaboration between the Department of Cardiology and the Clinical Research Centre at Hvidovre University Hospital. The research group will consist of the following persons:
Dr L. Vimal Hurry, MD, is project responsible. He is a junior doctor at the Department of Cardiology and doing research work beside his clinical employment.
Dr Ulrik Dixen, MD, PhD, is a consultant at the Department of Cardiology. Dr Ulrik Dixen has conducted AF research for several years and is experienced in planning and conducting clinical studies, as well as in supervising junior researchers.
Dr Nadia Landex, MD, PhD, is training in cardiology, currently at Roskilde University Hospital. She did her PhD in histochemistry and has used her experience in basic research to initiate research in biomarkers in AF at Hvidovre University Hospital, including research topic, project planning and the initial laboratory work.
Medical student Maha Alsawaf has written her bachelor thesis in the cardiology research group and has basic research experience. Maha Alsawaf will assist with inclusion of the patients.
Medical student Ema Rastoder is experienced in clinical research and skilled in patient communication. Ema Rastoder will assist with inclusion of patients.
Project members from the Clincial Research Centre are:
Head of Department Ove Andersen, MD, PhD, who has extensive experience in biomarker research at all stages from project development to implementation of research results.
Anne Langkilde, MSc, PhD, is likewise experienced in biomarker research, particularly in the prognostic importance of biomarkers in disease. Anne Langkilde has been a close collaborator in the initial projects regarding measurement of biomarkers in AF.
Together, the research team has experience of biomarker research as well as access to research laboratory with highly skilled laboratory technicians.
BLOOD SAMPLING AND MEASUREMENT OF SDF-1Α A blood sample of about 5 ml will be sampled by peripheral venepuncture and anticoagulated with heparin. Blood samples will be spun for 15 minutes at 1000g within 30 minutes of collection. The resulting plasma will be stored at -80°C until analysis. Levels of SDF-1α in the plasma will be determined using a commercially available ELISA kit according to the manufacturer's instructions.
Analyses will be performed at the Clinical Research Centre, Copenhagen University Hospital Hvidovre.
PATIENTS Patients are included from the in-patient department of the Department of Cardiology, Hvidovre University Hospital. Patients are eligible for inclusion if diagnosed with myocardial infarction, atrial fibrillation or heart failure, provided they do not suffer from malignant disease, diabetes mellitus types I or II and have a life expectancy of at least one year.
Exclusion criteria are based upon the fact that serum SDF-1α levels are elevated in malignant diseases as SDF-1α contributes to neoangiogenesis of the tumour mass, and SDF-1α levels have recently been demonstrated to be elevated in diabetes.
The investigators will include 20 patients with each of the cardiac conditions mentioned as well as a control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
PATIENTS WITH MYOCARDIAL INFARCTION Patients presenting with non-ST elevation myocardial infarction (NSTEMI) are included. The diagnostic criteria are symptoms of cardiac ischaemia (angina or angina-equivalent symptoms) and elevated troponin T (above 14 ng/mL) and/ or ECG changes of ischemia (horizontal or downsloping ST depression ≥ 0.5 mm at the J-point in ≥ 2 contiguous leads).
Patients are excluded if they are diagnosed with a "type 2 myocardial infarction", i.e. myocardial ischaemia due to mismatch between myocardial oxygen demand and supply due to conditions such as severe anaemia, arrhythmia or hypotension. Patients are also excluded if they are not referred for coronary angiography, if they have atrial fibrillation or if they have cardiac failure with LVEF ≤ 40%.
The SDF-1α levels of patients will be measured on the first day of hospitalization, after coronary angiography, before discharge (approximately day 3-5), and three months after inclusion.
PATIENTS WITH ATRIAL FIBRILLATION Patients presenting with ECG-documented atrial fibrillation are included if unstable, i.e. if heart rate exceeds 100 and in-patient treatment is indicated. Patients are excluded if they suffer from unstable ischaemic heart disease (unstable angina or myocardial infarction), heart failure with LVEF ≤ 40% or if the arrhythmia is secondary to another condition such as an infection.
SDF-1α levels will be measured on the first day of the hospitalization, at the time of discharge (after medical or electrical cardioversion or after stabilization of the heart rate) and three months after inclusion.
PATIENTS WITH CONGESTIVE HEART FAILURE Patients are included if presenting with decompensated heart failure. They must have symptoms of heart failure (dyspnoea and/ or oedema) severe enough to warrant in-patient treatment. The diagnosis must be confirmed by echocardiography showing LVEF ≤ 40%. Patients are excluded if suffering from unstable ischaemic heart disease (unstable angina or myocardial infarction) or atrial fibrillation.
The SDF-1α levels of will be measured on the first day of the hospitalization, after medical stabilization at the time of discharge, and three months after inclusion.
PATIENT INCLUSION AND DATA COLLECTION Patient inclusion will take place during three consecutive months. Patients are included within the first day of hospital admittance. Each day, members of the project group will screen all patients admitted within the last day and personally contact those eligible for inclusion. Patients will be informed verbally and given the written participant information. Patients will be given time for consideration and if they accept participation, they will be asked to sign the consent form. Due to the project design, according to which the first blood samples are to be taken within the first day of hospitalization, patients are asked to consent to project participation on the day of initial contact with the research group member. Conversations will be held in a private setting in the department, and patients are invited to bring relations, if they so prefer.
As regards the control group, these will be included from patients initially referred for outpatient evaluation at the Department of Cardiology, but in whom no cardiac disease is found. Members of the project group will screen the patients in the Outpatients Department and personally contact those eligible for inclusion in the control group. The control group will be selected so as to be age-matched with the patients. Information about the project will be provided as for the patients.
Based upon information in the patients' medical files, it will be registered whether patients suffer from hypertension, peripheral vascular disease, stroke, transient cerebral ischaemia, chronic obstructive pulmonary disease or renal insufficiency.
Medication at time of admittance to hospital and medication given during the hospitalization will be registered. Clinical status (dyspnoea, palpitations, oedema, blood pressure and heart rate) at the time of inclusion and at the time discharge from hospital will be noted. This information will be sought from patient files and the Kiso system used for recording vital parameters in patients.
The recorded information (pre-existing conditions, medication and clinical status at the two time-points) will be available for the project group. This information will be used for background demographics, in the evaluation of how levels of SDF-1α correlate to clinical status, and to allow for correction of factors, such as medication, on the levels of SDF-1α.
FOLLOW-UP All patients are expected to be seen in the Outpatients' Department 2-3 months after discharge from hospital. This appointment is part of the standard treatment and control plan for patients with AF, CHF and NSTEMI, respectively and not arranged as a part of the project. Certain information will be registered from the patient files at the time of follow-up: Clinical status (NYHA class, oedema, pulmonary congestion, and angina), heart rhythm, medication, and any intercurrent hospital admissions.
One year after inclusion, patient files will be reviewed and the following information registered: Whether the patient is alive and any cardiovascular rehospitalisation. In the case of hospitalization, the date of admission, duration and diagnosis will be registered. Statistical considerations and data analysis Baseline data of SDF-1α levels and patient demographics (including comorbidities and use of medication) will be evaluated using descriptive statistics. Normally distributed data will be presented as mean and standard deviation, whereas skewed data will be presented as median and range. If necessary, skewed data will be transformed.
The influence of patient characteristics (such as age, sex and comorbidities) on SDF-1α levels will be evaluated using multiple regression analysis with SDF-1α level as dependent variable and patient characteristics as explanatory variables. SDF-1α levels will be compared between the patient groups using analysis of variance (ANOVA).
Within each group of patients, the changes in SDF-1α levels over time (three time points) will be analysed using ANOVA.
The investigators have previously measured SDF-1α levels in patients with various types of AF (permanent versus paroxysmal). Based upon these results (SDF-1α levels and standard deviations in the different groups), the investigators have estimated that the proposed sample size of 20 patients in each disease group will confer the study sufficient statistical power.
The statistical analyses will be performed in collaboration with statistician Steen Ladelund (Clinical Research Centre, Hvidovre University Hospital).
THE RESEARCH GROUP
The study will be conducted in close collaboration between the Department of Cardiology and the Clinical Research Centre at Hvidovre University Hospital. The research group will consist of the following persons:
Dr L. Vimal Hurry, MD, is project responsible. He is a junior doctor at the Department of Cardiology and doing research work beside his clinical employment.
Dr Ulrik Dixen, MD, PhD, is a consultant at the Department of Cardiology. Dr Ulrik Dixen has conducted AF research for several years and is experienced in planning and conducting clinical studies, as well as in supervising junior researchers.
Dr Nadia Landex, MD, PhD, is training in cardiology, currently at Roskilde University Hospital. She did her PhD in histochemistry and has used her experience in basic research to initiate research in biomarkers in AF at Hvidovre University Hospital, including research topic, project planning and the initial laboratory work.
Medical student Maha Alsawaf has written her bachelor thesis in the cardiology research group and has basic research experience. Maha Alsawaf will assist with inclusion of the patients.
Medical student Ema Rastoder is experienced in clinical research and skilled in patient communication. Ema Rastoder will assist with inclusion of patients.
Project members from the Clincial Research Centre are:
Head of Department Ove Andersen, MD, PhD, who has extensive experience in biomarker research at all stages from project development to implementation of research results.
Anne Langkilde, MSc, PhD, is likewise experienced in biomarker research, particularly in the prognostic importance of biomarkers in disease. Anne Langkilde has been a close collaborator in the initial projects regarding measurement of biomarkers in AF.
Together, the research team has experience of biomarker research as well as access to research laboratory with highly skilled laboratory technicians.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atrial Fibrillation
Ischemic Heart Disease
Congestive Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DYNASDY
The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
Group Type
OTHER
DYNASDY
Intervention Type
OTHER
Measurement of SDF-1 alpha levels i patients' blood samples.
Control group
A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
Group Type
ACTIVE_COMPARATOR
DYNASDY
Intervention Type
OTHER
Measurement of SDF-1 alpha levels i patients' blood samples.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DYNASDY
Measurement of SDF-1 alpha levels i patients' blood samples.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients are included from the in-patient department of the Department of Cardiology, Hvidovre University Hospital. Patients are eligible for inclusion if diagnosed with one of the following diseases:
* myocardial infarction
* atrial fibrillation
* heart failure
* myocardial infarction
* atrial fibrillation
* heart failure
Exclusion Criteria
* malignant disease
* diabetes mellitus types I or II
* have a life expectancy of at least one year.
* diabetes mellitus types I or II
* have a life expectancy of at least one year.
Minimum Eligible Age
18 Years
Maximum Eligible Age
95 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Copenhagen University Hospital, Hvidovre
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lawkesh Vimal Hurry
M.D.
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nadia Landex, Ph.D.
Role: STUDY_CHAIR
Department of Cardiology, Roskilde University Hospital
Ema Ema Rastoder, MB
Role: STUDY_CHAIR
Department of Cardiology, Copenhagen University Hospital Hvidovre
Maha Maha Alsawaf, MB
Role: STUDY_CHAIR
Department of Cardiology, Copenhagen University Hospital Hvidovre
Anne Langkilde, MS, Ph.D.
Role: STUDY_DIRECTOR
Clinical Research Centre, Copenhagen University Hospital Hvidovre
Ove Andersen, M.D., Ph.D.
Role: STUDY_DIRECTOR
Clinical Research Centre, Copenhagen University Hospital Hvidovre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Copenhagen University Hospital Hvidovre
Hvidovre, Capital Region of Denmark, Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-15007626
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
New Biomarkers in Heart- and Renal Failure
NCT02830464
COMPLETED
Cardiac Structure and Function in Patients with Cystic Fibrosis
NCT06084468
ACTIVE_NOT_RECRUITING
The Relationship Between Heart Function and Metabolism in HFpEF Patients
NCT05053256
UNKNOWN
The Incidence of Thoracic Disc Herniation in Patients Presenting With Chronic Upper Back Pain
NCT05313997
COMPLETED
Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
NCT06435585
RECRUITING
Lymph Drainage in Heart Failure
NCT05240638
COMPLETED
NA
Congestive Heart Failure Surgical Treatmment With Autologous Stem Cell Therapy
NCT00480961
UNKNOWN
PHASE2
Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
NCT04269057
UNKNOWN
Adipose Tissue and Inflammation in Coronary Heart Disease
NCT02760914
ACTIVE_NOT_RECRUITING
Diabetic Cardiomyopathy and Heart Failure
NCT05571865
WITHDRAWN
NA
Oxidative Stress Markers and Cardiac Resynchronization Therapy (CRT) Outcomes
NCT01151553
TERMINATED
NA
Acute Cardiac Dysfunction in Critical Illnes
NCT05860504
RECRUITING
Pulsatile and Steady State Hemodynamics in Diastolic Heart Failure
NCT00720525
COMPLETED
Serum IGF1 on Female HFpEF Patients
NCT07015554
ENROLLING_BY_INVITATION
Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
NCT01416285
COMPLETED
Adipose Tissue Inflammation in HFpEF
NCT04886713
UNKNOWN
Hormone Deficiency in Heart Failure With Preserved Ejection Fraction
NCT02976350
COMPLETED
Functional Capacity in Anderson-Fabry Disease Patients
NCT06884358
RECRUITING
Cardiac Transplant Metabolomics With and Without Rejection
NCT05772442
NOT_YET_RECRUITING
Assessment of the Link Between Monomeric Functional Form Plasma Level of Vasostatin-1 and Occurrence of New Onset Atrial Fibrillation in Severe Intensive Care Patients
NCT03457155
UNKNOWN
NA
Strain X Cardiopulmonary Test
NCT02869178
UNKNOWN
Stress-induced Vascular Dysfunction: Evaluation of Endothelial Function in a Cohort of Patients With Takotsubo Syndrome
NCT01249599
COMPLETED
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
NCT00023595
COMPLETED
PHASE3
Predictors of Heart Failure After ST-segment Elevation Myocardial Infarction (HF-EXPRESS)
NCT02650934
UNKNOWN
Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging
NCT04022330
UNKNOWN
NA